Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Andreas Hochhaus
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Physiology
Concepts & Ideas
Procedures
Genes & Molecular Sequences
Sign-in to see full Profile
Network (preview)
95
Hehlmann, Rüdiger
34
Reiter, Andreas
31
Berger, Ute
30
Cross, Nicholas
24
Müller, Martin
21
Kreil, Sebastian
19
Hofheinz, Ralf-Dieter
17
Lahaye, Tanja
16
Erben, Philipp
15
Paschka, Peter
13
Queisser, Wolfgang
13
Saussele, Susanne
13
Seifarth, Wolfgang
12
Willer, Andreas
12
Ottmann, Oliver
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Andreas Hochhaus (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Hughes Timothy; Saglio Giuseppe; Branford Susan; Soverini Simona; Kim Dong-Wook; Müller Martin C; Martinelli Giovanni; Cortes Jorge; Beppu Lan; Gottardi Enrico; Kim Dongho; Erben Philipp; Shou Yaping; Haque Ariful; Gallagher Neil; Radich Jerald; Hochhaus Andreas
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(25):4204-10.
-
2009: Horisberger Karoline; Treschl Anne; Mai Sabine; Barreto-Miranda Manuel; Kienle Peter; Ströbel Philipp; Erben Philipp; Woernle Christoph; Dinter Dietmar; Kähler Georg; Hochhaus Andreas; Post Stefan; Willeke Frank; Wenz Frederik; Hofheinz Ralf-Dieter;
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
International journal of radiation oncology, biology, physics 2009;74(5):1487-93.
-
2009: Apperley Jane F; Cortes Jorge E; Kim Dong-Wook; Roy Lydia; Roboz Gail J; Rosti Gianantonio; Bullorsky Eduardo O; Abruzzese Elisabetta; Hochhaus Andreas; Heim Dominik; de Souza Carmino A; Larson Richard A; Lipton Jeffrey H; Khoury H Jean; Kim Hyeoung-Joon; Sillaber Christian; Hughes Timothy P; Erben Philipp; Van Tornout Jan; Stone Richard M
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3472-9.
-
2009: Horisberger Karoline; Erben Philipp; Muessle Benjamin; Woernle Christoph; Stroebel Philipp; Kaehler Georg; Wenz Frederik; Hochhaus Andreas; Post Stefan; Willeke Frank; Hofheinz Ralf-Dieter;
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
Anti-cancer drugs 2009;20(6):519-24.
-
2009: Hughes Timothy; Hochhaus Andreas
Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy.
Seminars in hematology 2009;46(2 Suppl 3):S11-5.
-
2009: Walz C; Score J; Mix J; Cilloni D; Roche-Lestienne C; Yeh R-F; Wiemels J L; Ottaviani E; Erben P; Hochhaus A; Baccarani M; Grimwade D; Preudhomme C; Apperley J; Martinelli G; Saglio G; Cross N C P; Reiter A;
The molecular anatomy of the FIP1L1-PDGFRA fusion gene.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(2):271-8.
-
2008: Erben Philipp; Horisberger Karoline; Muessle Benjamin; Müller Martin Christian; Treschl Anne; Ernst Thomas; Kähler Georg; Ströbel Philipp; Wenz Frederik; Kienle Peter; Post Stefan; Hochhaus Andreas; Willeke Frank; Hofheinz Ralf-Dieter
mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer.
International journal of radiation oncology, biology, physics 2008;72(5):1544-50.
-
2008: Metzgeroth Georgia; Walz Christoph; Erben Philipp; Popp Helena; Schmitt-Graeff Annette; Haferlach Claudia; Fabarius Alice; Schnittger Susanne; Grimwade David; Cross Nicholas C P; Hehlmann Rüdiger; Hochhaus Andreas; Reiter Andreas
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
British journal of haematology 2008;143(5):707-15.
-
2008: Branford Susan; Fletcher Linda; Cross Nicholas C P; Müller Martin C; Hochhaus Andreas; Kim Dong-Wook; Radich Jerald P; Saglio Giuseppe; Pane Fabrizio; Kamel-Reid Suzanne; Wang Y Lynn; Press Richard D; Lynch Kevin; Rudzki Zbigniew; Goldman John M; Hughes Timothy
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.
Blood 2008;112(8):3330-8.
-
2008: Ernst Thomas; Hoffmann Jana; Erben Philipp; Hanfstein Benjamin; Leitner Armin; Hehlmann Rüdiger; Hochhaus Andreas; Müller Martin C
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Haematologica 2008;93(9):1389-93.
-
2008: Fabarius Alice; Giehl Michelle; Rebacz Blanka; Krämer Alwin; Frank Oliver; Haferlach Claudia; Duesberg Peter; Hehlmann Rüdiger; Seifarth Wolfgang; Hochhaus Andreas
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib.
Haematologica 2008;93(8):1145-54.
-
2008: La Rosée Paul; Holm-Eriksen Susanne; Konig Heiko; Härtel Nicolai; Ernst Thomas; Debatin Julia; Mueller Martin C; Erben Philipp; Binckebanck Anja; Wunderle Lydia; Shou Yaping; Dugan Margaret; Hehlmann Ruediger; Ottmann Oliver G; Hochhaus Andreas
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Haematologica 2008;93(5):765-9.
-
2008: Hochhaus Andreas
First-Line management of CML: a state of the art review.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6 Suppl 2():S1-S10.
-
2008: Horisberger K; Hofheinz R D; Palma P; Volkert A K; Rothenhoefer S; Wenz F; Hochhaus A; Post S; Willeke F
Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?
International journal of colorectal disease 2008;23(3):257-64.
-
2008: Ernst Thomas; Erben Philipp; Müller Martin C; Paschka Peter; Schenk Thomas; Hoffmann Jana; Kreil Sebastian; La Rosée Paul; Hehlmann Rüdiger; Hochhaus Andreas
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Haematologica 2008;93(2):186-92.
-
2008: le Coutre Philipp; Ottmann Oliver G; Giles Francis; Kim Dong-Wook; Cortes Jorge; Gattermann Norbert; Apperley Jane F; Larson Richard A; Abruzzese Elisabetta; O'Brien Stephen G; Kuliczkowski Kazimierz; Hochhaus Andreas; Mahon Francois-Xavier; Saglio Giuseppe; Gobbi Marco; Kwong Yok-Lam; Baccarani Michele; Hughes Timothy; Martinelli Giovanni; Radich Jerald P; Zheng Ming; Shou Yaping; Kantarjian Hagop
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Blood 2008;111(4):1834-9.
-
2008: Müller M C; Erben P; Saglio G; Gottardi E; Nyvold C G; Schenk T; Ernst T; Lauber S; Kruth J; Hehlmann R; Hochhaus A;
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(1):96-102.
-
2008: Fabarius Alice; Duesberg Peter; Giehl Michelle; Seifarth Wolfgang; Hochhaus Andreas; Hehlmann Rüdiger
Genomic instability in context of the chromosomal theory.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2008;30(6):503-4.
-
2008: Ernst Thomas; Hoffmann Jana; Erben Philipp; Hehlmann Rüdiger; Hochhaus Andreas; Müller Martin C
Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(3):318-22.
-
2007: Kantarjian Hagop M; Giles Francis; Gattermann Norbert; Bhalla Kapil; Alimena Giuliana; Palandri Francesca; Ossenkoppele Gert J; Nicolini Franck-Emmanuel; O'Brien Stephen G; Litzow Mark; Bhatia Ravi; Cervantes Francisco; Haque Ariful; Shou Yaping; Resta Debra J; Weitzman Aaron; Hochhaus Andreas; le Coutre Philipp
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood 2007;110(10):3540-6.
-
2007: Deininger Michael W N; Cortes Jorge; Paquette Ron; Park Byung; Hochhaus Andreas; Baccarani Michele; Stone Richard; Fischer Thomas; Kantarjian Hagop; Niederwieser Dietger; Gambacorti-Passerini Carlo; So Charlene; Gathmann Insa; Goldman John M; Smith Douglas; Druker Brian J; Guilhot François
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Cancer 2007;110(7):1509-19.
-
2007: Ottmann Oliver; Dombret Hervé; Martinelli Giovanni; Simonsson Bengt; Guilhot Francois; Larson Richard A; Rege-Cambrin Giovanna; Radich Jerald; Hochhaus Andreas; Apanovitch Anne Marie; Gollerkeri Ashwin; Coutre Steven
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Blood 2007;110(7):2309-15.
-
2007: Giehl M; Fabarius A; Frank O; Erben P; Zheng C; Hafner M; Hochhaus A; Hehlmann R; Seifarth W
Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(9):1971-6.
-
2007: Fabarius Alice; Giehl Michelle; Frank Oliver; Spiess Birgit; Zheng Chun; Müller Martin C; Weiss Christel; Duesberg Peter; Hehlmann Rüdiger; Hochhaus Andreas; Seifarth Wolfgang
Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability.
British journal of haematology 2007;138(3):369-73.
-
2007: Kreil Sebastian; Pfirrmann Markus; Haferlach Claudia; Waghorn Katherine; Chase Andrew; Hehlmann Rüdiger; Reiter Andreas; Hochhaus Andreas; Cross Nicholas C P;
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.
Blood 2007;110(4):1283-90.
-
2007: Hehlmann Rüdiger; Hochhaus Andreas; Baccarani Michele;
Chronic myeloid leukaemia.
Lancet 2007;370(9584):342-50.
-
2007: Krämer Alwin; Reiter Andreas; Kruth Jens; Erben Philipp; Hochhaus Andreas; Müller Martin; Cross Nicholas C P; Jones Amy V; Ho Anthony D; Hensel Manfred
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
The lancet oncology 2007;8(7):658-60.
-
2007: Müller Martin C; Saglio Guiseppe; Lin Feng; Pfeifer Heike; Press Richard D; Tubbs Raymond R; Paschka Peter; Gottardi Enrico; O'Brien Steven G; Ottmann Oliver G; Stockinger Hubertus; Wieczorek Lothar; Merx Kirsten; König Heiko; Schwindel Uwe; Hehlmann Rüdiger; Hochhaus Andreas
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.
Haematologica 2007;92(7):970-3.
-
2007: Menzel H; von Bubnoff N; Hochhaus A; Haferlach C; Peschel C; Duyster J
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib.
Bone marrow transplantation 2007;40(1):83-4.
-
2007: Pfeifer Heike; Wassmann Barbara; Pavlova Anna; Wunderle Lydia; Oldenburg Johannes; Binckebanck Anja; Lange Thoralf; Hochhaus Andreas; Wystub Silvia; Brück Patrick; Hoelzer Dieter; Ottmann Oliver G
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood 2007;110(2):727-34.
-
2007: Utikal Jochen; Ugurel Selma; Kurzen Hjalmar; Erben Philipp; Reiter Andreas; Hochhaus Andreas; Nebe Thomas; Hildenbrand Ralf; Haberkorn Uwe; Goerdt Sergij; Schadendorf Dirk
Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
Archives of dermatology 2007;143(6):736-40.
-
2007: Konig Heiko; Härtel Nicolai; Schultheis Beate; Schatz Michael; Lorentz Christian; Melo Junia V; Hehlmann Rüdiger; Hochhaus Andreas; La Rosée Paul
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Haematologica 2007;92(6):838-41.
-
2007: Fabarius Alice; Haferlach Claudia; Müller Martin C; Erben Philipp; Lahaye Tanja; Giehl Michelle; Frank Oliver; Seifarth Wolfgang; Hehlmann Rüdiger; Hochhaus Andreas
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
Haematologica 2007;92(6):834-7.
-
2007: Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller M C; Beneke H; Müller L; Del Valle F; Aulitzky W E; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker S J; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross N C P; Reiter A
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(6):1183-8.
-
2007: Hehlmann Rüdiger; Berger Ute; Pfirrmann Markus; Heimpel Hermann; Hochhaus Andreas; Hasford Joerg; Kolb Hans-Jochem; Lahaye Tanja; Maywald Ole; Reiter Andreas; Hossfeld Dieter K; Huber Christoph; Löffler Helmut; Pralle Hans; Queisser Wolfgang; Tobler Andreas; Nerl Christoph; Solenthaler Max; Goebeler Mariele E; Griesshammer Martin; Fischer Thomas; Kremers Stephan; Eimermacher Hartmut; Pfreundschuh Michael; Hirschmann Wolf-Dietrich; Lechner Klaus; Wassmann Barbara; Falge Christiane; Kirchner Hartmut H; Gratwohl Alois
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Blood 2007;109(11):4686-92.
-
2007: Jovanovic Jelena V; Score Joannah; Waghorn Katherine; Cilloni Daniela; Gottardi Enrico; Metzgeroth Georgia; Erben Philipp; Popp Helena; Walz Christoph; Hochhaus Andreas; Roche-Lestienne Catherine; Preudhomme Claude; Solomon Ellen; Apperley Jane; Rondoni Michela; Ottaviani Emanuela; Martinelli Giovanni; Brito-Babapulle Finella; Saglio Giuseppe; Hehlmann Rüdiger; Cross Nicholas C P; Reiter Andreas; Grimwade David
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Blood 2007;109(11):4635-40.
-
2007: Guilhot Francois; Apperley Jane; Kim Dong-Wook; Bullorsky Eduardo O; Baccarani Michele; Roboz Gail J; Amadori Sergio; de Souza Carmino A; Lipton Jeffrey H; Hochhaus Andreas; Heim Dominik; Larson Richard A; Branford Susan; Muller Martin C; Agarwal Prasheen; Gollerkeri Ashwin; Talpaz Moshe
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Blood 2007;109(10):4143-50.
-
2007: Fruehauf Stefan; Topaly Julian; Buss Eike C; Fischer Thomas; Ottmann Oliver G; Emmerich Bertold; Müller Martin C; Schuld Peter; Balleisen Leopold; Hehlmann Rüdiger; Ho Anthony D; Hochhaus Andreas
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Cancer 2007;109(8):1543-9.
-
2007: Kantarjian Hagop M; Cortes Jorge; Guilhot Francçois; Hochhaus Andreas; Baccarani Michele; Lokey Lee
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Cancer 2007;109(7):1365-75.
-
2007: Cortes Jorge; Rousselot Philippe; Kim Dong-Wook; Ritchie Ellen; Hamerschlak Nelson; Coutre Steven; Hochhaus Andreas; Guilhot Francois; Saglio Giuseppe; Apperley Jane; Ottmann Oliver; Shah Neil; Erben Philipp; Branford Susan; Agarwal Prasheen; Gollerkeri Ashwin; Baccarani Michele
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Blood 2007;109(8):3207-13.
-
2007: Willeke F; Horisberger K; Kraus-Tiefenbacher U; Wenz F; Leitner A; Hochhaus A; Grobholz R; Willer A; Kähler G; Post S; Hofheinz R-D
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
British journal of cancer 2007;96(6):912-7.
-
2007: Hochhaus Andreas; Kantarjian Hagop M; Baccarani Michele; Lipton Jeffrey H; Apperley Jane F; Druker Brian J; Facon Thierry; Goldberg Stuart L; Cervantes Francisco; Niederwieser Dietger; Silver Richard T; Stone Richard M; Hughes Timothy P; Muller Martin C; Ezzeddine Rana; Countouriotis Athena M; Shah Neil P
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Blood 2007;109(6):2303-9.
-
2007: Wang Ying; Cai Dali; Brendel Cornelia; Barett Christine; Erben Philipp; Manley Paul W; Hochhaus Andreas; Neubauer Andreas; Burchert Andreas
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.
Blood 2007;109(5):2147-55.
-
2007: Walz Christoph; Metzgeroth Georgia; Haferlach Claudia; Schmitt-Graeff Annette; Fabarius Alice; Hagen Volker; Prümmer Otto; Rauh Stefan; Hehlmann Rüdiger; Hochhaus Andreas; Cross Nicholas C P; Reiter Andreas
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
Haematologica 2007;92(2):163-9.
-
2007: Hochhaus Andreas; Erben Philipp; Ernst Thomas; Mueller Martin C
Resistance to targeted therapy in chronic myelogenous leukemia.
Seminars in hematology 2007;44(1 Suppl 1):S15-24.
-
2006: Hofheinz Ralf-Dieter; Kubicka Stefan; Wollert Jörg; Arnold Dirk; Hochhaus Andreas
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Onkologie 2006;29(12):563-7.
-
2006: Hofheinz Ralf-Dieter; Horisberger Karoline; Woernle Christoph; Wenz Frederik; Kraus-Tiefenbacher Uta; Kähler Georg; Dinter Dietmar; Grobholz Rainer; Heeger Steffen; Post Stefan; Hochhaus Andreas; Willeke Frank
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
International journal of radiation oncology, biology, physics 2006;66(5):1384-90.
-
2006: Branford S; Cross N C P; Hochhaus A; Radich J; Saglio G; Kaeda J; Goldman J; Hughes T
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(11):1925-30.
-
2006: Saussele S; Adam K; Hochhaus A; Béné M C; Büchner T; Burnett A; Finazzi G; Fonatsch C; Gluckman E; Gökbuget N; Grimwade D J; Haferlach T; Hallek M; Hasford J; Hoelzer D; Ljungman P; Niederwieser D; Serve H; Simonsson B; de Witte T J; Hehlmann R;
[Clinical research at the European LeukemiaNet]
Deutsche medizinische Wochenschrift (1946) 2006;131(43):2423-6.
-
2006: Walz Christoph; Curtis Claire; Schnittger Susanne; Schultheis Beate; Metzgeroth Georgia; Schoch Claudia; Lengfelder Eva; Erben Philipp; Müller Martin C; Haferlach Torsten; Hochhaus Andreas; Hehlmann Rüdiger; Cross Nicholas C P; Reiter Andreas
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Genes, chromosomes & cancer 2006;45(10):950-6.
-
2006: Frank O; Brors B; Fabarius A; Li L; Haak M; Merk S; Schwindel U; Zheng C; Müller M C; Gretz N; Hehlmann R; Hochhaus A; Seifarth W
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(8):1400-7.
-
2006: Hughes Timothy; Deininger Michael; Hochhaus Andreas; Branford Susan; Radich Jerald; Kaeda Jaspal; Baccarani Michele; Cortes Jorge; Cross Nicholas C P; Druker Brian J; Gabert Jean; Grimwade David; Hehlmann Rüdiger; Kamel-Reid Suzanne; Lipton Jeffrey H; Longtine Janina; Martinelli Giovanni; Saglio Giuseppe; Soverini Simona; Stock Wendy; Goldman John M
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Blood 2006;108(1):28-37.
-
2006: Kantarjian Hagop; Giles Francis; Wunderle Lydia; Bhalla Kapil; O'Brien Susan; Wassmann Barbara; Tanaka Chiaki; Manley Paul; Rae Patricia; Mietlowski William; Bochinski Kathy; Hochhaus Andreas; Griffin James D; Hoelzer Dieter; Albitar Maher; Dugan Margaret; Cortes Jorge; Alland Leila; Ottmann Oliver G
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
The New England journal of medicine 2006;354(24):2542-51.
-
2006: Zheng C; Li L; Haak M; Brors B; Frank O; Giehl M; Fabarius A; Schatz M; Weisser A; Lorentz C; Gretz N; Hehlmann R; Hochhaus A; Seifarth W
Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(6):1028-34.
-
2006: Jones Amy V; Silver Richard T; Waghorn Katherine; Curtis Claire; Kreil Sebastian; Zoi Katerina; Hochhaus Andreas; Oscier David; Metzgeroth Georgia; Lengfelder Eva; Reiter Andreas; Chase Andrew J; Cross Nicholas C P
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.
Blood 2006;107(8):3339-41.
-
2006: Maywald O; Pfirrmann M; Berger U; Breitscheidel L; Gratwohl A; Kolb H-J; Beelen D W; Tobler A; Metzgeroth G; Gnad S U; Hochhaus A; Hasford J; Hehlmann R; Reiter A;
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(3):477-84.
-
2005: Hofheinz R D; Dittrich C; Jakupec M A; Drescher A; Jaehde U; Gneist M; Graf von Keyserlingk N; Keppler B K; Hochhaus A
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).
International journal of clinical pharmacology and therapeutics 2005;43(12):590-1.
-
2005: Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann O G; Duyster J; Hochhaus A; Neubauer A
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(10):1774-82.
-
2005: Fabarius A; Giehl M; Frank O; Duesberg P; Hochhaus A; Hehlmann R; Seifarth W
Induction of centrosome and chromosome aberrations by imatinib in vitro.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(9):1573-8.
-
2005: Jones Amy V; Kreil Sebastian; Zoi Katerina; Waghorn Katherine; Curtis Claire; Zhang Lingyan; Score Joannah; Seear Rachel; Chase Andrew J; Grand Francis H; White Helen; Zoi Christine; Loukopoulos Dimitris; Terpos Evangelos; Vervessou Elisavet-Christine; Schultheis Beate; Emig Michael; Ernst Thomas; Lengfelder Eva; Hehlmann Rüdiger; Hochhaus Andreas; Oscier David; Silver Richard T; Reiter Andreas; Cross Nicholas C P
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
Blood 2005;106(6):2162-8.
-
2005: Hofheinz Ralf-Dieter; Gnad-Vogt Senta Ulrike; Beyer Ulrich; Hochhaus Andreas
Liposomal encapsulated anti-cancer drugs.
Anti-cancer drugs 2005;16(7):691-707.
-
2005: Hehlmann Rüdiger; Berger Ute; Hochhaus Andreas
Chronic myeloid leukemia: a model for oncology.
Annals of hematology 2005;84(8):487-97.
-
2005: Giehl M; Fabarius A; Frank O; Hochhaus A; Hafner M; Hehlmann R; Seifarth W
Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(7):1192-7.
-
2005: Hartung G; Hofheinz R-D; Dencausse Y; Sturm J; Kopp-Schneider A; Dietrich G; Fackler-Schwalbe I; Bornbusch D; Gonnermann M; Wojatschek C; Lindemann W; Eschenburg H; Jost K; Edler L; Hochhaus A; Queisser W
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study.
Onkologie 2005;28(6-7):347-50.
-
2005: Berger U; Maywald O; Pfirrmann M; Lahaye T; Hochhaus A; Reiter A; Hasford J; Heimpel H; Hossfeld D K; Kolb H-J; Löffler H; Pralle H; Queisser W; Hehlmann R;
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(6):984-9.
-
2005: Walz C; Chase A; Schoch C; Weisser A; Schlegel F; Hochhaus A; Fuchs R; Schmitt-Gräff A; Hehlmann R; Cross N C P; Reiter A
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(6):1005-9.
-
2005: Hasford J; Pfirrmann M; Hochhaus A
How long will chronic myeloid leukemia patients treated with imatinib mesylate live?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(4):497-9.
-
2005: Ugurel S; Hildenbrand R; Zimpfer A; La Rosée P; Paschka P; Sucker A; Keikavoussi P; Becker J C; Rittgen W; Hochhaus A; Schadendorf D
Lack of clinical efficacy of imatinib in metastatic melanoma.
British journal of cancer 2005;92(8):1398-405.
-
2005: Crossman Lucy C; Mori Motomi; Hsieh Yi-Ching; Lange Thoralf; Paschka Peter; Harrington Christina A; Krohn Knut; Niederwieser Dietger W; Hehlmann Rüdiger; Hochhaus Andreas; Druker Brian J; Deininger Michael W N
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.
Haematologica 2005;90(4):459-64.
-
2005: Reiter Andreas; Walz Christoph; Watmore Ann; Schoch Claudia; Blau Ilona; Schlegelberger Brigitte; Berger Ute; Telford Nick; Aruliah Shilani; Yin John A; Vanstraelen Danny; Barker Helen F; Taylor Peter C; O'Driscoll Aisling; Benedetti Fabio; Rudolph Cornelia; Kolb Hans-Jochem; Hochhaus Andreas; Hehlmann Rüdiger; Chase Andrew; Cross Nicholas C P
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Cancer research 2005;65(7):2662-7.
-
2005: Lahaye Tanja; Riehm Birte; Berger Ute; Paschka Peter; Müller Martin C; Kreil Sebastian; Merx Kirsten; Schwindel Uwe; Schoch Claudia; Hehlmann Rüdiger; Hochhaus Andreas
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Cancer 2005;103(8):1659-69.
-
2005: Gnad-Vogt Senta Ulrike; Hofheinz Ralf-Dieter; Saussele Susanne; Kreil Sebastian; Willer Andreas; Willeke Frank; Pilz Lothar; Hehlmann Rüdiger; Hochhaus Andreas
Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial.
Anti-cancer drugs 2005;16(4):435-40.
-
2005: Demehri S; Paschka P; Schultheis B; Lange T; Koizumi T; Sugimoto T; Branford S; Lim L C; Kegel T; Martinelli G; Hochhaus A; Druker B J; Deininger M W N
e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(4):681-4.
-
2005: Hofheinz Ralf-Dieter; von Gerstenberg-Helldorf Bolko; Wenz Frederik; Gnad Ulrike; Kraus-Tiefenbacher Uta; Müldner Albrecht; Hehlmann Rüdiger; Post Stefan; Hochhaus Andreas; Willeke Frank
Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(7):1350-7.
-
2005: Hofheinz Ralf-Dieter; Gnad-Vogt Ulrike; Wein Axel; Saussele Susanne; Kreil Sebastian; Pilz Lothar; Hehlmann Rüdiger; Hochhaus Andreas
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Anti-cancer drugs 2005;16(1):39-45.
-
2005: Neuhof Dirk; Neumayer Florian; Einbeck Wolfgang; Haschemian Kai; Mai Sabine K; Hochhaus Andreas; Willeke Frank; Rudi Jochen; Debus Jürgen; Wenz Frederik
Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer.
Acta oncologica (Stockholm, Sweden) 2005;44(2):168-73.
-
2004: Hochhaus A; Berger U; Hehlmann R
[Therapy of chronic myelogenous leukemia in 2004]
Deutsche medizinische Wochenschrift (1946) 2004;129(40):2122-7.
-
2004: Hofheinz R-D; Hartmann J T; Willer A; Oechsle K; Hartung G; Gnad U; Saussele S; Kreil S; Bokemeyer C; Hehlmann R; Hochhaus A
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial.
British journal of cancer 2004;91(5):834-8.
-
2004: Faderl Stefan; Hochhaus Andreas; Hughes Timothy
Monitoring of minimal residual disease in chronic myeloid leukemia.
Hematology/oncology clinics of North America 2004;18(3):657-70, ix-x.
-
2004: Hochhaus Andreas; Hughes Timothy
Clinical resistance to imatinib: mechanisms and implications.
Hematology/oncology clinics of North America 2004;18(3):641-56, ix.
-
2004: Hofheinz R-D; Willer A; Weisser A; Gnad U; Saussele S; Kreil S; Hartmann J T; Hehlmann R; Hochhaus A
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
British journal of cancer 2004;90(10):1893-7.
-
2004: Burchert Andreas; Cai Dali; Hofbauer Lorenz C; Samuelsson Magnus K R; Slater Emily P; Duyster Justus; Ritter Markus; Hochhaus Andreas; Müller Rolf; Eilers Martin; Schmidt Manuel; Neubauer Andreas
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.
Blood 2004;103(9):3480-9.
-
2004: Berger U; Engelich G; Reiter A; Hochhaus A; Hehlmann R;
Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
Annals of hematology 2004;83(4):258-64.
-
2004: Hofheinz Ralf-Dieter; Nguyen Xuan-Duc; Buchheidt Dieter; Kerowgan Mohammed; Hehlmann Rüdiger; Hochhaus Andreas
Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient.
Cancer chemotherapy and pharmacology 2004;53(3):276-7.
-
2004: Paschka Peter; Merx Kirsten; Hochhaus Andreas
Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance.
Acta haematologica 2004;112(1-2):85-92.
-
2004: Müller Martin C; Hördt Tanja; Paschka Peter; Merx Kirsten; La Rosée Paul; Hehlmann Rüdiger; Hochhaus Andreas
Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia.
Acta haematologica 2004;112(1-2):30-3.
-
2004: Hochhaus A
Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Annals of hematology 2004;83 Suppl 1():S65-6.
-
2003: Hochhaus A
A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reached.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(12):2383-4.
-
2003: Müller M C; Gattermann N; Lahaye T; Deininger M W N; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld D K; Schneller F; Krause S W; Nerl C; Sayer H G; Ottmann O G; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(12):2392-400.
-
2003: Sacha Tomasz; Hochhaus Andreas; Hanfstein Benjamin; Müller Martin C; Rudzki Zbigniew; Czopek Jacek; Wolska-Smolen Teresa; Czekalska Sylwia; Salamanchuk Zoriana; Jakóbczyk Malgorzata; Skotnicki Aleksander B
ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.
Leukemia research 2003;27(12):1163-6.
-
2003: Hughes Tim P; Kaeda Jaspal; Branford Susan; Rudzki Zbigniew; Hochhaus Andreas; Hensley Martee L; Gathmann Insa; Bolton Ann E; van Hoomissen Iris C; Goldman John M; Radich Jerald P;
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
The New England journal of medicine 2003;349(15):1423-32.
-
2003: Berger U; Engelich G; Maywald O; Pfirrmann M; Hochhaus A; Reiter A; Metzgeroth G; Gnad U; Hasford J; Heinze B; Heimpel H; Hossfeld D K; Kolb H-J; Löffler H; Pralle H; Queisser W; Hehlmann R;
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(9):1820-6.
-
2003: Paschka P; Müller M C; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(9):1687-94.
-
2003: Brummendorf Tim H; Ersoz Inci; Hartmann Ulrike; Balabanov Stefan; Wolke Holger; Paschka Peter; Lahaye Tanja; Berner Birgit; Bartolovic Kerol; Kreil Sebastian; Berger Ute; Gschaidmeier Harald; Bokemeyer Carsten; Hehlmann Rudiger; Dietz Klaus; Lansdorp Peter M; Kanz Lothar; Hochhaus Andreas
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Annals of the New York Academy of Sciences 2003;996():26-38.
-
2003: Fruehauf S; Topaly J; Schad M; Paschka P; Gschaidmeier H; Zeller W J; Hochhaus A; Ho A D
Imatinib restores expression of CD62L in BCR-ABL-positive cells.
Journal of leukocyte biology 2003;73(5):600-3.
-
2003: Hochhaus Andreas
Cytogenetic and molecular mechanisms of resistance to imatinib.
Seminars in hematology 2003;40(2 Suppl 2):69-79.
-
2003: Hofheinz R-D; Weisser A; Willer A; Hehlmann R; Hochhaus A
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Onkologie 2003;26(2):161-4.
-
2003: Wassmann B; Scheuring U; Thiede C; Pfeifer H; Bornhäuser M; Griesinger F; Hochhaus A; Schleyer E; Gschaidmeier H; Hoelzer D; Ottmann O G
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Bone marrow transplantation 2003;31(7):611-4.
-
2003: O'Brien Stephen G; Guilhot François; Larson Richard A; Gathmann Insa; Baccarani Michele; Cervantes Francisco; Cornelissen Jan J; Fischer Thomas; Hochhaus Andreas; Hughes Timothy; Lechner Klaus; Nielsen Johan L; Rousselot Philippe; Reiffers Josy; Saglio Giuseppe; Shepherd John; Simonsson Bengt; Gratwohl Alois; Goldman John M; Kantarjian Hagop; Taylor Kerry; Verhoef Gregor; Bolton Ann E; Capdeville Renaud; Druker Brian J;
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
The New England journal of medicine 2003;348(11):994-1004.
-
2003: Reiter Andreas; Saussele Susanne; Grimwade David; Wiemels Joseph L; Segal Mark R; Lafage-Pochitaloff Marina; Walz Christoph; Weisser Andreas; Hochhaus Andreas; Willer Andreas; Reichert Anja; Büchner Thomas; Lengfelder Eva; Hehlmann Rüdiger; Cross Nicholas C P
Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia.
Genes, chromosomes & cancer 2003;36(2):175-88.
-
2003: Brümmendorf Tim H; Ersöz Inci; Hartmann Ulrike; Bartolovic Kerol; Balabanov Stefan; Wahl Alexandra; Paschka Peter; Kreil Sebastian; Lahaye Tanja; Berger Ute; Gschaidmeier Harald; Bokemeyer Carsten; Hehlmann Rüdiger; Dietz Klaus; Lansdorp Peter M; Kanz Lothar; Hochhaus Andreas
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Blood 2003;101(1):375-6.
-
2003: Burchert Andreas; Wölfl Stefan; Schmidt Manuel; Brendel Cornelia; Denecke Barbara; Cai Dali; Odyvanova Larissa; Lahaye Tanja; Müller Martin C; Berg Thomas; Gschaidmeier Harald; Wittig Burghardt; Hehlmann Rüdiger; Hochhaus Andreas; Neubauer Andreas
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Blood 2003;101(1):259-64.
-
2002: Müller M C; Merx K; Weisser A; Kreil S; Lahaye T; Hehlmann R; Hochhaus A
Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(12):2395-9.
-
2002: Hofheinz Ralf; Hartung Gernot; Samel Stefan; Emig Michael; Pilz Lothar; Willeke Frank; Hochhaus Andreas; Hehlmann Rüdiger; Queisser Wolfgang
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Anti-cancer drugs 2002;13(10):999-1004.
-
2002: Hochhaus A; Kreil S; Corbin A S; La Rosée P; Müller M C; Lahaye T; Hanfstein B; Schoch C; Cross N C P; Berger U; Gschaidmeier H; Druker B J; Hehlmann R
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(11):2190-6.
-
2002: Hochhaus A; Berger U; Reiter A; Engelich G; Lahaye T; Kreil S; Merx K; Müller M C; Hehlmann R
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group]
Der Internist 2002;43(10):1228, 1231-8, 1241-4.
-
2002: Müller M C; Lahaye T; Hochhaus A
[Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells]
Deutsche medizinische Wochenschrift (1946) 2002;127(42):2205-7.
-
2002: Merx K; Müller M C; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(9):1579-83.
-
2002: Ottmann Oliver G; Druker Brian J; Sawyers Charles L; Goldman John M; Reiffers Jose; Silver Richard T; Tura Sante; Fischer Thomas; Deininger Michael W; Schiffer Charles A; Baccarani Michele; Gratwohl Alois; Hochhaus Andreas; Hoelzer Dieter; Fernandes-Reese Sofia; Gathmann Insa; Capdeville Renaud; O'Brien Stephen G
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Blood 2002;100(6):1965-71.
-
2002: Fischer T; Reifenrath C; Hess G R; Corsetti M T; Kreil S; Beck J; Meinhardt P; Beltrami G; Schuch B; Gschaidmeier H; Hehlmann R; Hochhaus A; Carella A; Huber C
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(7):1220-8.
-
2002: Hofheinz R-D; Hartung G; Samel S; Hochhaus A; Pichlmeier U; Post S; Hehlmann R; Queisser W
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Onkologie 2002;25(3):255-60.
-
2002: Baxter E Joanna; Hochhaus Andreas; Bolufer Pascual; Reiter Andreas; Fernandez José M; Senent Leonor; Cervera José; Moscardo Federico; Sanz Miguel A; Cross Nicholas C P
The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.
Human molecular genetics 2002;11(12):1391-7.
-
2002: Talpaz Moshe; Silver Richard T; Druker Brian J; Goldman John M; Gambacorti-Passerini Carlo; Guilhot Francois; Schiffer Charles A; Fischer Thomas; Deininger Michael W N; Lennard Anne L; Hochhaus Andreas; Ottmann Oliver G; Gratwohl Alois; Baccarani Michele; Stone Richard; Tura Sante; Mahon Francois-Xavier; Fernandes-Reese Sofia; Gathmann Insa; Capdeville Renaud; Kantarjian Hagop M; Sawyers Charles L
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
-
2002: Hochhaus A
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease]
Deutsche medizinische Wochenschrift (1946) 2002;127(9):451-6.
-
2002: Schultheis Beate; Carapeti-Marootian Melina; Hochhaus Andreas; Weisser Andreas; Goldman John M; Melo Junia V
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.
Blood 2002;99(5):1766-75.
-
2002: Hochhaus A; Berger U; Reiter A; Hehlmann R
[Current pharmacotherapy of chronic myeloid leukemia]
Der Internist 2002;43(2):270-83.
-
2002: Hochhaus Andreas; Berger Ute; Reiter Andreas; Lahaye Tanja; Kreil Sebastian; Hehlmann Rüdiger
[Drug therapy of chronic myeloid leukemia]
Medizinische Klinik (Munich, Germany : 1983) 2002;97 Suppl 1():7-15.
-
2002: Hochhaus Andreas
Detection and quantification of leukemia-specific rearrangements.
Methods in molecular medicine 2002;68():67-96.
-
2001: de la Fuente J; Merx K; Steer E J; Müller M; Szydlo R M; Maywald O; Berger U; Hehlmann R; Goldman J M; Cross N C; Melo J V; Hochhaus A;
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia.
Blood 2001;98(9):2879-80.
-
2001: Hochhaus A; Lahaye T; Kreil S; Berger U; Metzgeroth G; Hehlmann R
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology]
Onkologie 2001;24 Suppl 5():65-71.
-
2001: Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross N C; Linkesch W; Druker B J; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
Roots of clinical resistance to STI-571 cancer therapy.
Science (New York, N.Y.) 2001;293(5538):2163.
-
2001: Reiter A; Hochhaus A; Berger U; Kuhn C; Hehlmann R
AraC-based pharmacotherapy of chronic myeloid leukaemia.
Expert opinion on pharmacotherapy 2001;2(7):1129-35.
-
2001: Schmidt M; Hochhaus A; Nitsche A; Hehlmann R; Neubauer A
Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha.
Blood 2001;97(11):3648-50.
-
2000: Saussele S; Weisser A; Müller M C; Emgi M; La Rosée P; Paschka P; Kuhn C; Willer A; Hehlmann R; Hochhaus A
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(11):2006-10.
-
2000: Schmidt M; Hochhaus A; König-Merediz S A; Brendel C; Proba J; Hoppe G J; Wittig B; Ehninger G; Hehlmann R; Neubauer A
Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(19):3331-8.
-
2000: Lengfelder E; Reichert A; Schoch C; Haase D; Haferlach T; Löffler H; Staib P; Heyll A; Seifarth W; Saussele S; Fonatsch C; Gassmann W; Ludwig W D; Hochhaus A; Beelen D; Aul C; Sauerland M C; Heinecke A; Hehlmann R; Wörmann B; Hiddemann W; Büchner T
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(8):1362-70.
-
2000: Hochhaus A; Weisser A; La Rosée P; Emig M; Müller M C; Saussele S; Reiter A; Kuhn C; Berger U; Hehlmann R; Cross N C
Detection and quantification of residual disease in chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(6):998-1005.
-
2000: Hochhaus A; Reiter A; Saussele S; Reichert A; Emig M; Kaeda J; Schultheis B; Berger U; Shepherd P C; Allan N C; Hehlmann R; Goldman J M; Cross N C
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
Blood 2000;95(1):62-6.
-
1999: Hehlmann R; Hochhaus A; Kolb H J; Hasford J; Gratwohl A; Heimpel H; Siegert W; Finke J; Ehninger G; Holler E; Berger U; Pfirrmann M; Muth A; Zander A; Fauser A A; Heyll A; Nerl C; Hossfeld D K; Löffler H; Pralle H; Queisser W; Tobler A
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
Blood 1999;94(11):3668-77.
-
1999: Emig M; Saussele S; Wittor H; Weisser A; Reiter A; Willer A; Berger U; Hehlmann R; Cross N C; Hochhaus A
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(11):1825-32.
-
1999: Krämer A; Hörner S; Willer A; Fruehauf S; Hochhaus A; Hallek M; Hehlmann R
Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(5):2087-92.
-
1998: Krämer A; Hochhaus A; Saussele S; Reichert A; Willer A; Hehlmann R
Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(6):893-8.
-
1998: Hochhaus A; Berger U; Krämer A; Reiter A; Seifarth W; Willer A; Hehlmann R
Congress Report: XIX symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Mannheim/Heidelberg, Germany, July 13 - 18, 1997.
European journal of medical research 1998;3(4):216-22.
-
1998: Lengfelder E; Hochhaus A; Kronawitter U; Höche D; Queisser W; Jahn-Eder M; Burkhardt R; Reiter A; Ansari H; Hehlmann R
Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages.
British journal of haematology 1998;100(1):15-23.
-
1998: Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
Chronic myelogenous leukemia: molecular and cellular aspects.
Journal of cancer research and clinical oncology 1998;124(12):643-60.
-
1998: Hochhaus A; Berger U; Krämer A; Reiter A; Seifarth W; Willer A; Hehlmann R
XIX Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, July 13-18 Mannheim/Heidelberg, Germany, 1997.
Journal of cancer research and clinical oncology 1998;124(3-4):220-30.
-
1998: Hochhaus A; Reiter A; Skladny H; Reichert A; Saussele S; Hehlmann R
Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1998;144():36-45.
-
1997: Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman J M; Cross N C
Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 3():541-4.
-
1997: Hehlmann R; Willer A; Heimpel H; Hasford J; Kolb H J; Pralle H; Hossfeld D K; Queisser W; Löffler H; Hochhaus A; Tobler A; Lengfelder E; Berger U; Leib-Mösch C
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 3():506-11.
-
1997: Reiter A; Skladny H; Hochhaus A; Seifarth W; Heimpel H; Bartram C R; Cross N C; Hehlmann R
Molecular response of CML patients treated with interferon-alpha monitored by quantitative Southern blot analysis. German chronic myeloid leukaemia (CML) Study Group.
British journal of haematology 1997;97(1):86-93.
-
1997: Hehlmann R; Ansari H; Hasford J; Heimpel H; Hossfeld D K; Kolb H J; Löffler H; Pralle H; Queisser W; Reiter A; Hochhaus A
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
British journal of haematology 1997;97(1):76-85.
-
1996: Hochhaus A; Hehlmann R
[Chronic myeloid leukemia. Current strategies in diagnosis, therapy and follow-up]
Der Internist 1996;37(10):1013-21.
-
1996: Aguiar R C; Sill H; Hochhaus A; Goldman J M; Cross N C
Molecular investigation of secondary chronic myeloid leukemia.
Blood 1996;88(7):2808-9.
-
1996: Hochhaus A; Reiter A; Skladny H; Melo J V; Sick C; Berger U; Guo J Q; Arlinghaus R B; Hehlmann R; Goldman J M; Cross N C
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
Blood 1996;88(6):2236-40.
-
1996: Al-Jehani F; Hochhaus A; Spencer A; Goldman J M; Melo J V
Expression of the LH2 gene in chronic myeloid leukaemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(7):1122-6.
-
1996: van Rhee F; Hochhaus A; Lin F; Melo J V; Goldman J M; Cross N C
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Blood 1996;87(12):5213-7.
-
1996: Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman J M; Cross N C
Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.
Bone marrow transplantation 1996;17 Suppl 3():S41-4.
-
1996: Hehlmann R; Heimpel H; Hossfeld D K; Hasford J; Kolb H J; Löffler H; Pralle H; Queisser W; Hochhaus A; Tichelli A; Fett W; Schmitz N; Reiter A; Griesshammer M; Pfeifer W; Bümler M; Kamp T; Tobler A; Eimermacher H; Kuse R; Berger U; Ansari H
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
Bone marrow transplantation 1996;17 Suppl 3():S21-4.
-
1996: Melo J V; Hochhaus A; Yan X H; Goldman J M
Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia.
British journal of haematology 1996;92(3):684-6.
-
1996: Sill H; Aguiar R C; Schmidt H; Hochhaus A; Goldman J M; Cross N C
Mutational analysis of the p15 and p16 genes in acute leukaemias.
British journal of haematology 1996;92(3):681-3.
-
1996: Hochhaus A; Lin F; Reiter A; Skladny H; Mason P J; van Rhee F; Shepherd P C; Allan N C; Hehlmann R; Goldman J M; Cross N C
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
Blood 1996;87(4):1549-55.
-
1995: Hochhaus A; Lin F; Reiter A; Skladny H; van Rhee F; Shepherd P C; Allan N C; Hehlmann R; Goldman J M; Cross N C
Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
British journal of haematology 1995;91(1):126-31.
-
1995: van Rhee F; Marks D I; Lin F; Szydlo R M; Hochhaus A; Treleaven J; Delord C; Cross N C; Goldman J M
Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(2):329-35.
-
1994: Hehlmann R; Heimpel H; Hasford J; Kolb H J; Pralle H; Hossfeld D K; Queisser W; Löffler H; Hochhaus A; Heinze B
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Blood 1994;84(12):4064-77.
-
1994: Hehlmann R; Ansari H; Adelberger V; Heinze B; Hossfeld K; Hochhaus A; Heimpel H
New perspectives with interferon alpha. The German CML study group experience.
Bone marrow transplantation 1994;14 Suppl 3():S14-20.
-
1993: Griesshammer M; Hehlmann R; Hochhaus A; Talpaz M; Tura S; Stryckmans P; Allan N C; Tanzer J; Kolb H J; Heimpel H
Interferon in chronic myeloid leukemia. A workshop report.
Annals of hematology 1993;67(2):101-6.
-
1993: Hehlmann R; Heimpel H; Kolb H J; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser W P; Essers U; Falge C
The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Leukemia & lymphoma 1993;11 Suppl 1():159-68.
-
1991: Hehlmann R; Heimpel H; Heinze B; Georgii A; Kolb H J; Hossfeld D K; von Wussow P; Hochhaus A; Griesshammer M; Diehl V
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)]
Onkologie 1991;14(1):66-73.
-
1990: Hochhaus A; Mindner K; Ostermann G; Höche D
[Aggregative behavior and calcium content of platelets in thrombocythemia and thrombocytosis]
Folia haematologica (Leipzig, Germany : 1928) 1990;117(6):765-70.
-
1989: Hochhaus A; Höche D; Mindner K; Ostermann G; Meyer M
[Megakaryocytic myelosis--clinical aspects, morphology and platelet function]
Klinische Wochenschrift 1989;67(2):51-9.
-
1988: Hochhaus A; Wutke K; Meyer M
[Hereditary elliptocytosis with detection of a membrane protein defect of erythrocytes]
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1988;43(5):128-9.
-
1988: Mindner K; Ostermann G; Hochhaus A; Höche D; Till U
Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis.
Folia haematologica (Leipzig, Germany : 1928) 1988;115(4):461-4.
Sign-in to see more
